Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Apr;65(4):621–623. doi: 10.1038/bjc.1992.126

A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.

M J Lind 1, B M Cantwell 1, M J Millward 1, A Robinson 1, M Proctor 1, D Simmons 1, J Carmichael 1, A L Harris 1
PMCID: PMC1977567  PMID: 1314071

Abstract

Thirty patients with advanced epithelial ovarian cancer were treated with the luteinising hormone releasing agonist, goserelin. There were two partial responses lasting 40 and 105 weeks respectively. In addition five patients had disease stabilisation lasting 25, 35, 40, 66 and 70 weeks respectively and 23 patients had progressive disease. No significant or unexpected toxicities occurred. This minimally toxic therapy halted disease progression for 6 months or more in 23% of patients, the majority of whom were heavily pretreated. There were five early deaths due to disease progression. The use of goserelin in patients with epithelial ovarian cancers resistant to or relapsing soon after first line platinum based chemotherapy needs to be further evaluated.

Full text

PDF
621

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blackledge G., Lawton F., Redman C., Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer. 1989 Apr;59(4):650–653. doi: 10.1038/bjc.1989.132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bruckner H. W., Motwani B. T. Treatment of advanced refractory ovarian carcinoma with a gonadotropin-releasing hormone analogue. Am J Obstet Gynecol. 1989 Nov;161(5):1216–1218. doi: 10.1016/0002-9378(89)90669-8. [DOI] [PubMed] [Google Scholar]
  3. Dowsett M., Cantwell B., Lal A., Jeffcoate S. L., Harris A. L. Suppression of postmenopausal ovarian steroidogenesis with the luteinizing hormone-releasing hormone agonist goserelin. J Clin Endocrinol Metab. 1988 Apr;66(4):672–677. doi: 10.1210/jcem-66-4-672. [DOI] [PubMed] [Google Scholar]
  4. Emons G., Pahwa G. S., Brack C., Sturm R., Oberheuser F., Knuppen R. Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Clin Oncol. 1989 Feb;25(2):215–221. doi: 10.1016/0277-5379(89)90011-4. [DOI] [PubMed] [Google Scholar]
  5. Harris A. L., Carmichael J., Cantwell B. M., Dowsett M. Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer. Br J Cancer. 1989 Jan;59(1):97–99. doi: 10.1038/bjc.1989.19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Howell A., Mackintosh J., Jones M., Redford J., Wagstaff J., Sellwood R. A. The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol. 1988 Oct;24(10):1567–1572. doi: 10.1016/0277-5379(88)90046-6. [DOI] [PubMed] [Google Scholar]
  7. Kavanagh J. J., Roberts W., Townsend P., Hewitt S. Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer. J Clin Oncol. 1989 Jan;7(1):115–118. doi: 10.1200/JCO.1989.7.1.115. [DOI] [PubMed] [Google Scholar]
  8. Langdon S. P., Hawkes M. M., Lawrie S. S., Hawkins R. A., Tesdale A. L., Crew A. J., Miller W. R., Smyth J. F. Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines. Br J Cancer. 1990 Aug;62(2):213–216. doi: 10.1038/bjc.1990.263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Mählck C. G., Bäckström T., Kjellgren O. Plasma level of estradiol in patients with ovarian malignant tumors. Gynecol Oncol. 1988 Jul;30(3):313–320. doi: 10.1016/0090-8258(88)90245-4. [DOI] [PubMed] [Google Scholar]
  10. Rao B. R., Slotman B. J., Geldof A. A., Dinjens W. N. Correlation between tumor histology, steroid receptor status, and adenosine deaminase complexing protein immunoreactivity in ovarian cancer. Int J Gynecol Pathol. 1990;9(1):47–54. doi: 10.1097/00004347-199001000-00004. [DOI] [PubMed] [Google Scholar]
  11. Slotman B. J., Rao B. R. Ovarian cancer (review). Etiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy and endocrine therapy. Anticancer Res. 1988 May-Jun;8(3):417–434. [PubMed] [Google Scholar]
  12. Williams M. R., Walker K. J., Turkes A., Blamey R. W., Nicholson R. I. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer. 1986 May;53(5):629–636. doi: 10.1038/bjc.1986.106. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES